-
Triamcinolone (B1859): Research Workflow Guide
2026-08-15
Triamcinolone (SKU B1859) is a synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid signaling, inflammation, and immunosuppression. This guide addresses solvent selection, storage, assay controls, and troubleshooting; the compound is intended for scientific research only and should not be used for diagnostic, therapeutic, or clinical purposes.
-
AG-490 (Tyrphostin B42): JAK2/EGFR Insights
2026-08-15
AG-490, also called Tyrphostin B42, is a reported multi-kinase inhibitor that targets JAK2, EGFR, and ErbB2. Its strongest research value is pathway dissection in cytokine-responsive and tumor-associated immune-cell models, while direct activity against exosomal SNORD52-driven macrophage polarization remains unverified.
-
AKTIP Biomarker Discovery in Fibrolamellar Carcinoma
2026-08-14
A 2025 study integrated transcriptomic datasets, WGCNA, machine learning, drug-response resources, and molecular simulations to identify AKTIP as a candidate diagnostic and prognostic biomarker for fibrolamellar carcinoma. The work also nominated four compounds for future investigation, while its qRT-PCR and computational results highlight both the translational potential and the validation requirements of biomarker discovery in this rare liver cancer.
-
Amorolfine Hydrochloride in Yeast Membrane Studies
2026-08-14
Use Amorolfine Hydrochloride as a pathway-oriented antifungal reagent for connecting sterol-related membrane stress with ploidy, growth, and resistance phenotypes. This workflow combines disciplined solvent control, time-resolved measurements, and the cell-size insights of a recent budding-yeast study.
-
SIRT6, Nucleolar Remodeling, and Proteostasis
2026-08-13
The 2026 Aging Cell study identifies SIRT6 as a regulator of proteostasis that links chromatin organization and nucleolar activity to global protein synthesis and folding capacity. Its cellular and C. elegans evidence suggests that excessive translation caused by SIRT6 loss promotes proteotoxic stress and neurodegeneration-related phenotypes, while lowering translation can partially restore stress tolerance.
-
Intravesical p21 mRNA–LNP Therapy for Bladder Cancer
2026-08-13
The reference study develops chemically modified p21 mRNA encapsulated in lipid nanoparticles for localized intravesical treatment of bladder cancer. Its data connect bladder-restricted protein expression with suppression of tumor growth, cell-cycle signaling, DNA damage responses, and apoptosis, while highlighting the translational potential and remaining limitations of local mRNA delivery.
-
Temozolomide Workflows for Glioma DNA-Damage Studies
2026-08-12
Build reproducible Temozolomide assays around DMSO handling, time-resolved DNA-damage readouts, and ATRX-aware experimental design. The workflow also shows how to test combination effects with RTK or PDGFR inhibitors without confusing chemical instability, vehicle toxicity, and genuine genotype-dependent sensitivity.
-
SAR131675: Selective VEGFR-3 Inhibitor
2026-08-12
SAR131675 is a selective ATP-competitive VEGFR-3 inhibitor with nanomolar biochemical and cellular activity. Its preclinical profile supports lymphangiogenesis, angiogenesis, and tumor-growth studies, but discontinued development and limited formulation data constrain translational interpretation.
-
Resiquimod (R-848) in Tumor Ablation
2026-08-11
Learn how Resiquimod (R-848) can be integrated into thermal-ablation assays to connect localized drug delivery with TLR7/8-driven immune activation. This workflow emphasizes formulation controls, temperature mapping, immune readouts, and troubleshooting for translational cancer immunotherapy research.
-
HRP Goat Anti-Rabbit IgG (H+L) Antibody Guide
2026-08-10
HRP Goat Anti-Rabbit IgG (H+L) Antibody, SKU K1223, provides an HRP-labeled secondary reagent for detecting rabbit primary antibodies in Western blotting, ELISA, IHC, and IC. It is intended for research workflows only; assay-specific dilution, blocking, washing, and substrate conditions still require empirical optimization.
-
8-Chloroadenosine RNA Workflow Guide
2026-08-09
Learn how to use 8-Chloroadenosine as a controlled RNA-synthesis perturbation in transcriptional regulation research, RNA decay experiments, and exploratory cancer research. This practical guide combines stock-preparation guidance, transcript-decay workflows, assay controls, and troubleshooting for more interpretable molecular biology results.
-
PD 0332991: From G1 Arrest to Translation
2026-08-08
A translational framework for using PD 0332991 (Palbociclib) HCl to connect CDK4/6 biology, Rb dependence, cell-cycle pharmacodynamics, and biomarker-informed DNA-repair research.
-
Diclofenac in Human Intestinal Organoid Assays
2026-08-07
Diclofenac is a non-selective COX inhibitor that can serve as both a mechanistic perturbation and a model compound in human intestinal organoid workflows. This article explains how to connect cyclooxygenase inhibition, intestinal metabolism, barrier biology, and translational assay decisions without overstating what organoid data can prove.
-
JHU-083: Enhancing Glutaminase Pathway Research Workflows
2026-08-07
JHU-083, a potent 6-diazo-5-oxo-L-norleucine precursor from APExBIO, enables precision glutaminase inhibition in neurological and experimental cerebral malaria models. This article explores optimized protocols, troubleshooting strategies, and how insights from GSTA1-driven glutathione depletion refine redox and excitotoxicity research.
-
Tβ4 Promotes Angiogenesis in Critical Limb Ischemia via Notc
2026-08-06
The referenced study demonstrates that thymosin-β4 (Tβ4) enhances angiogenesis in critical limb ischemia (CLI) by activating the Notch and NF-κB signaling pathways. These findings provide new mechanistic insights for developing therapeutic strategies targeting vascular regeneration in CLI and highlight the utility of pathway-specific inhibitors in dissecting angiogenic signaling.
453 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page